Health House International Limited announced that it has signed a non-exclusive distribution agreement (Distribution Agreement) with Dragonfly Biosciences Limited (Dragonfly). The Distribution Agreement, with an initial term of two years with an additional renewal term of a further two years, will further expand Health House's product portfolio for medicinal cannabis within Australia. Up until March 2021 the Australian Therapeutic Goods Administration has approved over 100,000 patient applications for medicinal cannabis.